Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2-Breast Cancer Patient With High Tumor Mutational Burden

doi:10.3389/fonc.2020.588080

	Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2-Breast Cancer Patient With High Tumor Mutational Burden
	Wang, Rong 2,3; Yang, Yuchen 1; Ye, Wei-Wu 2,3; Xiang, Jianxing 1; Chen, Songan 1; Zou, Wei-Bin 2,3; Wang, Xiao-Jia 2,3; Chen, Tianhui 3,4; Cao, Wen-Ming 2,3
刊名	FRONTIERS IN ONCOLOGY
	2021-02-09
卷号	10
关键词	breast cancer immunotherapy biomarker TMB NGS molecular monitoring
ISSN号	2234-943X
DOI	10.3389/fonc.2020.588080
通讯作者	Cao, Wen-Ming(caowm@zjcc.org.cn)
英文摘要	Endocrine treatment plus CDK4/6 inhibitors have become standard of care for estrogen receptor positive (ER+) breast cancer. Although immune checkpoint inhibitors (ICIs) have shown promising antitumor activity in a variety of cancer types, only limited success has been achieved for metastatic breast cancer (mBC) patients, especially the ER+ subtype, which usually exhibit lower tumor mutation burden (TMB) compared with other subtypes and therefore perceived as immunologically quiescent. Here we present a case of an ER+/HER2- but TMB-high mBC patient who had significant response to combination therapy with anti-PD-1 antibody camrelizumab and vinorelbine and obtained partial response (PR) with a progression-free survival (PFS) of 5 months after failure of multiple lines of therapy. Our case indicates that TMB may serve as a potential biomarker in immunotherapy selection for normally immunologically "cold" tumors such as ER+ mBC, also molecular monitoring during the whole treatment course plays an important role in patient management.
资助项目	Natural Science Foundation of Zhejiang Province, China[LY17H160038] ; Key Research-Development Program of Zhejiang Province[2020C04012] ; Key Research-Development Program of Zhejiang Province[2019C04001] ; Key Research-Development Program of Zhejiang Province[2017C03013] ; Health Bureau of Zhejiang Province, China[2017RC014]
WOS研究方向	Oncology
语种	英语
出版者	FRONTIERS MEDIA SA
WOS记录号	WOS:000620353700001
资助机构	Natural Science Foundation of Zhejiang Province, China ; Key Research-Development Program of Zhejiang Province ; Health Bureau of Zhejiang Province, China
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/120640]
专题	中国科学院合肥物质科学研究院
通讯作者	Cao, Wen-Ming
作者单位	1.Burning Rock Biotech, Guangzhou, Peoples R China 2.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Breast Med Oncol, Canc Hosp, Hangzhou, Peoples R China 3.Chinese Acad Sci, Inst Canc & Basic Med IBMC, Hangzhou, Peoples R China 4.Univ Chinese Acad Sci, Dept Canc Prevent, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Wang, Rong,Yang, Yuchen,Ye, Wei-Wu,et al. Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2-Breast Cancer Patient With High Tumor Mutational Burden[J]. FRONTIERS IN ONCOLOGY,2021,10.
APA	Wang, Rong.,Yang, Yuchen.,Ye, Wei-Wu.,Xiang, Jianxing.,Chen, Songan.,...&Cao, Wen-Ming.(2021).Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2-Breast Cancer Patient With High Tumor Mutational Burden.FRONTIERS IN ONCOLOGY,10.
MLA	Wang, Rong,et al."Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2-Breast Cancer Patient With High Tumor Mutational Burden".FRONTIERS IN ONCOLOGY 10(2021).